Cytokinetics (CYTK) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results
April 30, 2015 4:00 PM EDTCompany is Readying to Initiate a Phase III Clinical Trial of Tirasemtiv in Patients With ALS following Recent Meetings With FDA and EMA
Completion of Patient Enrollment in COSMIC-HF Enable Results Expected Later This Year
SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the first quarter of 2015 were $4.4 million, compared to $8.0 million during the same period in 2014. The net loss for the... More
